英語ページ

Publications 2007

  1. Akihama, S., Sato, K., Satoh, S., Tsuchiya, N., Kato, T., Komatsuda, A., Hirokawa, M., Sawada, K., Nanjo, H. and Habuchi, T. (2007) Bone marrow-derived cells mobilized by granulocyte-colony stimulating factor facilitate vascular regeneration in mouse kidney after ischemia/reperfusion injury. Tohoku J. Exp. Med., 213, 341-349.
  2. Fukuda, H., Tsuchiya, N., Narita, S., Kumazawa, T., Horikawa, Y., Inoue, T., Saito, M., Yuasa, T., Matsuura, S., Satoh, S., Ogawa, O. and Habuchi, T. (2007) Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol. Rep., 18, 1155-1163.
  3. Horikawa, Y., Kumazawa, T., Narita, S., Inoue, T., Yuasa, T., Matsuura, S., Nanjo, H., Satoh, S., Tsuchiya, N. and Habuchi, T. (2007) Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy. Int. J. Clin. Oncol., 12, 131-136.
  4. Inoue, K., Miura, m., Satoh, S., Kagaya, H., Saito, M., Habuchi, T. and Suzuki, T. (2007) Influence of UGT1A7 and UGT1A9 intron I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther. Drug. Monit., 29, 299-304.
  5. Inoue, T., Obara, T., Saito, M., Kumazawa, T., Yuasa, T., Matuura, S., Tsuchiya, N., Satoh, S. and Habuchi, T. (2007) Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients. Hinyokika Kiyo 53, 613-618.
  6. Inoue, T., Nishiyama, H., Yoshimura, K., Ito, N., Kamoto, T., Habuchi, T. and Ogawa, O. (2007) Solitary upper ureteral malakoplakia successfully diagnosed by ureteroscopic biopsy and treated conservatively. Int .J. Urol., 14, 859-861.
  7. Kagaya, H., Inoue, K., Miura, M., Satoh, S., Saito, M., Tada, H., Habuchi, T. and Suzuki, T. (2007) Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol., 63, 279-288.
  8. Kagaya, H., Inoue, K., Miura M, Satoh, S., Saito, M., Tada, H., Habuchi, T. and Suzuki, T. (2007) Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol., 63, 279-288.
  9. Kageyama, S., Iwaki, H., Inoue, H., Isono, T., Yuasa, T., Nogawa, M., Maekawa, T., Ueda, M., Kajita, Y., Ogawa, O., Toguchida, J. and Yoshiki, T. A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. Proteomics Clin. Appl., 1, 192-199.
  10. Kanzaki, M., Kakinuma, H., Kumazawa, T., Inoue, T., Saito, M., Narita, S., Yuasa, T., Tsuchiya, N. and Habuchi, T. (2007) Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol. Rep., 17, 761-767.
  11. Miura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T. and Habuchi, T. (2007) Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol., 63, 1161-1169.
  12. Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., Sagae, Y., Habuchi, T. and Suzuki, T. (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm. Drug. Dispos., 28, 167-175.
  13. Miura, M., Inoue, K., Satoh, S., Itoh, Y., Kagaya, H., Tada, H., Tanaka, Y., Habuchi, T. and Suzuki, T. (2007) Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. Clin. Drug. Investig., 27, 251-258.
  14. Miura, M., Inoue, K., Satoh S., Itoh, Y., Kagaya, H., Tada, H., Tanaka, Y., Habuch, T. and Suzuki, T. (2007) Influence of cytochrome P450 (CYP)3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metabolizer renal transplant recipients Clin. Drug Investig., 27, 251-258.
  15. Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., Sagae, Y., Habuchi, T. and Suzuki, T. (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in Renal Transplant Recipients. Biopharm. Drug Dispos., 21, 167-175.
  16. Saito, M., Satoh, S., Inoue, T., Yuasa, T., Komatsuda, A., Tsuchiya, N. and Habuchi, T. (2007) Clinical course and pathological findings of successful second ABO-incompatible renal transplantation in a patient with donor specific anti-HLA antibody. Clin. Transplant., 21 (suppl 18), 54-59.
  17. Satoh, S., Saito, M., Inoue, K., Miura, M., Komatsuda, A. and Habuchi, T. (2007) Association of cytokine polymorphisms with subclinical progressive chronic allograft nephropathy in Japanese renal transplant recipients: preliminary study. Int. J. Urol., 14, 990-994.

メニューを開く